TWINPEAK
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- NCT05482893 ↗
- Recruiting
- Phanes Therapeutics
- Focused
We haven't built an HCP commentary report on TWINPEAK (spevatamig; spevatamig plus FOLFOX; spevatamig plus pembrolizumab plus FOLFOX in advanced gastrointestinal cancers) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TWINPEAK so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC); Colorectal Cancer
- Interventions
- Spevatamig (PT886); Paclitaxel; Gemcitabine; Abraxane; KEYTRUDA® (pembrolizumab); FOLFOX; CAPOX; FOLFIRINOX; TAS 102; Bevacizumab; Gemcitabine Combined With Cisplatin; NALIRIFOX
- Arms
- Dose Escalation · Experimental
- Dose Expansion · Experimental
- Combination Expansion with Chemotherapy or Targeted Therapy · Experimental
- Combination Expansion with KEYTRUDA® (pembrolizumab) · Experimental
- Enrollment
- 350 (estimated)
- Primary outcomes
- To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.
- To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.
- To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.
- Sponsor
- Phanes Therapeutics with Merck Sharp & Dohme LLC
- Start
- Mar 15, 2023
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05482893 · updated Sep 28, 2026